Eyelid allergic contact dermatitis after intravitreal injections of anti-vascular endothelial growth factor: What is the culprit? A report of 3 cases

Contact Dermatitis. 2018 Aug;79(2):103-104. doi: 10.1111/cod.13000. Epub 2018 Apr 30.

Authors

Tullia de Risi-Pugliese¹, Emmanuelle Amsler¹, Evelyne Collet², Camille Francès^{1

3}, Annick Barbaud^{1

3}, Catherine Pecquet¹, Angèle Soria^{1

3

4}

Affiliations

¹ AP-HP, Dermatology and Allergology Department, Hôpital Tenon, Paris, France.
² Dermatology Department, Hôpital le Bocage, Dijon, France.
³ Faculty of Medicine, Sorbonne Université, Paris, France.
⁴ Immunology and Infectious Diseases Department (Cimi-Paris), Inserm 1135, Paris, France.

PMID: 29708276
DOI: 10.1111/cod.13000

No abstract available

Keywords: allergic contact dermatitis; azithromycin; case report; eyelids; intravitreal injections.

Publication types

Case Reports

MeSH terms

Aged
Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / adverse effects*
Anti-Bacterial Agents / administration & dosage
Anti-Bacterial Agents / adverse effects*
Azithromycin / administration & dosage
Azithromycin / adverse effects*
Blepharitis / chemically induced*
Blepharitis / diagnosis
Dermatitis, Allergic Contact / diagnosis
Dermatitis, Allergic Contact / etiology*
Diagnosis, Differential
Drug Eruptions / diagnosis
Drug Eruptions / etiology*
Female
Humans
Intravitreal Injections
Ranibizumab / administration & dosage
Ranibizumab / adverse effects
Receptors, Vascular Endothelial Growth Factor / administration & dosage
Recombinant Fusion Proteins / administration & dosage
Recombinant Fusion Proteins / adverse effects
Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

Angiogenesis Inhibitors
Anti-Bacterial Agents
Recombinant Fusion Proteins
Vascular Endothelial Growth Factor A
aflibercept
Azithromycin
Receptors, Vascular Endothelial Growth Factor
Ranibizumab